What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620%

Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (NASDAQ:PVLA), reported the exercise of 4,302 stock options immediately converted and sold as common shares for a transaction value of approximately $476,000 according to the SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price ($110.73).

How does this transaction impact Goin's overall exposure to Palvella Therapeutics?While direct ownership of common stock is now zero, Goin maintains 17,219 options outstanding (direct), preserving her economic interest via potential future share conversion.

What does the 100.00% direct holdings sale indicate in the context of prior trading activity?This action completes a sequence of option exercises and immediate sales.

What is the current market context relative to the transaction price?Shares were sold at a weighted average of around $110.73 per share, while the stock closed at $148.21 as of June 26, 2026, reflecting an increase from the transaction level and a one-year gain of nearly 620%.

Palvella Therapeutics develops and advances QTORIN rapamycin, a topical gel for rare dermatological conditions.

The company operates a clinical-stage bi

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/know-476-000-palvella-therapeutics-163154872.html)